William Garner, CEO of Urigen Pharmaceuticals, said: “In co-operation with the University of California at San Diego (UCSD), we have amended the annual license payments to ensure that we are in compliance with our obligations.
“Amending this license with UCSD is an important step in re-organizing and re-focusing our efforts to enhance shareholder value.”